41835-08-9

Usage

Uses

Used in Pharmaceutical Industry:
1-(3-Cyanophenyl)-2-thiourea is used as a pharmaceutical agent for its potential antifungal and antiviral properties, offering a broad-spectrum activity against various pathogens and contributing to the development of new therapeutic agents.
Used in Chemical Industry:
As a corrosion inhibitor, 1-(3-Cyanophenyl)-2-thiourea is utilized in the protection of metal surfaces from corrosion, making it a valuable component in various industrial applications, particularly in the manufacturing and maintenance of metal structures and equipment.
Used in Coordination Chemistry:
1-(3-Cyanophenyl)-2-thiourea serves as a potential ligand in coordination chemistry, playing a crucial role in the formation of coordination compounds and contributing to the advancement of inorganic chemistry and materials science.
Used in Organic Synthesis:
1-(3-CYANOPHENYL)-2-THIOUREA is employed as a reagent in organic synthesis, facilitating various chemical reactions and contributing to the synthesis of complex organic molecules, which can be used in a wide range of applications, from pharmaceuticals to specialty chemicals.

InChI:InChI=1/C8H7N3S/c9-5-6-2-1-3-7(4-6)11-8(10)12/h1-4H,(H3,10,11,12)

Upstream product

• 40229-47-8 (5-amino-[1,2,4]dithiazol-3-ylidene)-phenyl-amine 
• 19981-17-0 sodium cyanamide 
• 103-72-0 phenyl isothiocyanate 
• 53243-40-6 5-anilino-1-ethyl-3-imino-3H-[1,2,4]dithiazolium; iodide 
• 40229-47-8 (5-amino-[1,2,4]dithiazol-3-ylidene)-phenyl-amine 
• 420-04-2 CYANAMID 
• 62-53-3 aniline 

Downstream Products

• 2209-23-6 2,4,6-triimino-1,3,5-triphenyl-hexahydro-1,3,5-triazine 
• 80762-11-4 C₁₂H₁₄N₄ 
• 67026-92-0 C₁₃H₁₈N₄ 
• 67026-93-1 N''-cyano-N-phenyl-N'(1,2,2-trimethylpropyl)guanidine 
• 127749-53-5 C₁₆H₁₆N₄ 
• 603-54-3 N,N-diphenylurea 
• 13807-17-5 4-amino-2-anilino-thiazole-5-carboxylic acid methyl ester 
• 790663-62-6 1-(3-(1H-imidazol-1-yl)propyl)-2-cyano-3-phenylguanidine 
• 14998-02-8 2-(phenylamino)thiazolo[4,5-d]pyrimidin-7(6H)-one 

Relevant academic research and scientific papers

Design, Synthesis, and Biological Evaluation of 6-Substituted Thieno[3,2- d]pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors

The clinical evidence for the success of tyrosine kinase inhibitors in combination with microtubule-targeting agents prompted us to design and develop single agents that possess both epidermal growth factor receptor (EGFR) kinase and tubulin polymerization inhibitory properties. A series of 6-aryl/heteroaryl-4-(3′,4′,5′-trimethoxyanilino)thieno[3,2-d]pyrimidine derivatives were discovered as novel dual tubulin polymerization and EGFR kinase inhibitors. The 4-(3′,4′,5′-trimethoxyanilino)-6-(p-tolyl)thieno[3,2-d]pyrimidine derivative 6g was the most potent compound of the series as an antiproliferative agent, with half-maximal inhibitory concentration (IC50) values in the single- or double-digit nanomolar range. Compound 6g bound to tubulin in the colchicine site and inhibited tubulin assembly with an IC50 value of 0.71 μM, and 6g inhibited EGFR activity with an IC50 value of 30 nM. Our data suggested that the excellent in vitro and in vivo profile of 6g may be derived from its dual inhibition of tubulin polymerization and EGFR kinase.

Hindered phenolic aminothiazoles – Synthesis, α-glucosidase and α-amylase inhibitory and antioxidant activities

Base-catalysed heterocyclization of either N-aryl-N'-[imino(nitroamino)methyl]thioureas or N-aryl-N'-cyanothioureas by reaction with 2-bromo-1-(2,6-di-t-butyl-4-hydroxyphenyl)ethanone afforded 4-amino-2-(arylamino)--5-(3,5-di-t-butyl-4-hydroxybenzoyl)thia

Design, synthesis, X-ray crystallographic analysis, and biological evaluation of thiazole derivatives as potent and selective inhibitors of human dihydroorotate dehydrogenase

Human dihydroorotate dehydrogenase (HsDHODH) is a flavin-dependent mitochondrial enzyme that has been certified as a potential therapeutic target for the treatment of rheumatoid arthritis and other autoimmune diseases. On the basis of lead compound 4, which was previously identified as potential HsDHODH inhibitor, a novel series of thiazole derivatives were designed and synthesized. The X-ray complex structures of the promising analogues 12 and 33 confirmed that these inhibitors bind at the putative ubiquinone binding tunnel and guided us to explore more potent inhibitors, such as compounds 44, 46, and 47 which showed double digit nanomolar activities of 26, 18, and 29 nM, respectively. Moreover, 44 presented considerable anti-inflammation effect in vivo and significantly alleviated foot swelling in a dose-dependent manner, which disclosed that thiazole-scaffold analogues can be developed into the drug candidates for the treatment of rheumatoid arthritis by suppressing the bioactivity of HsDHODH.

Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors

2,7-Diamino-thiazolo[4,5-d]pyrimidine analogues were synthesized as novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Representative compounds showed potent and selective EGFR inhibitory activities and inhibited in vitro cellular p

Inhibitors for human glutaminyl cyclase by structure based design and bioisosteric replacement

The inhibition of human glutaminyl cyclase (hQC) has come into focus as a new potential approach for the treatment of Alzheimer's disease. The hallmark of this principle is the prevention of the formation of Aβ 3,11(pE)-40,42, as these Aβ-speci

Process for the preparation of tri-nitrogen containing heteroaryl-diamine derivatives useful as pharmaceutical agents and methods of producing pharmaceutical agents

This invention provides a process for producing at least one tri-nitrogen containing heteroaryl-diamine derivatives, which are useful as pharmaceutical agents and components, particularly as IMPDH inhibitors, comprising reacting an isothiocyanate with a h

METHOD OF TREATING OR PREVENTION OF FIBRILLATION OF THE HEART

A method for the treatment and prevention of fibrillation using one or more potassium channel activators. Also, disclosed is a process for the preparation of compounds of the formula STR1 and the tautomeric forms STR2 wherein R''and R" are as defined here